Southampton-based biotech, Synairgen, stated that their preliminary results of a medical trial suggests a new treatment for coronavirus that will reduce the number of patients who needs intensive care.
The treatment uses a protein called interferon beta which is inhaled directly into the infected patient’s lungs using a nebuliser, with hopes that it will trigger an immune response. Research shows that the treatment could cut down the probability of a patient in hospital from developing severe symptoms by 79%.
Synairgen claims that the patients who were tested were more likely to recover to the point that they were able to do everyday activities. Additionally, the patients who received the treatment have reduced the number of days spent in hospital from an average of nine days to six days.
Image credit: www.businessmag.co.uk
